Survodutide
Dual GLP-1 + glucagon.
- Sizes available
- 10mg
- Lab certificate (COA)
- Supplier-published sample
· Research-grade only · Not for human consumption · 21+ ·
Dual GLP-1 + glucagon. Weight loss with reduced liver fat. Phase 2 / 3.
Mechanism · Dual GLP-1 + glucagon receptor agonist. Boehringer Ingelheim Phase 2 / 3 trials.
Best for. Not for.
Best for
- Obesity with concurrent MASH or NASH liver disease.
- Comfortable trying the Phase 3 MERIDIAN trial compound.
- Insufficient response to GLP-1 monotherapy. Needs the glucagon arm.
Not for
- GLP-1 class warnings (MTC / MEN-2, pancreatitis).
- Glucagon stimulation raises glucose. Use caution in T2DM.
- Pregnancy, nursing, or type 1 diabetes.
- Still Phase 2 / 3. No FDA approval.
Mechanism, dose, ramp, risk.
- Mechanism
- Dual GLP-1 + glucagon agonist. Phase 3 trial compound.Source · PEPVERA editorial
- Target dose
- Research only. See protocol.Source · PEPVERA editorial
- Ramp
- Slow. Phase 3 protocols mirror Retatrutide.Source · PEPVERA editorial
- Risks
- Limited human data outside trial.Source · PEPVERA editorial
Compared to its siblings.
Survodutide
Dual GLP-1 + glucagon. Weight loss with reduced liver fat. Phase 2 / 3.
Pros
- · Adds glucagon arm vs tirzepatide for stronger liver-fat reduction.
- · Comparable Phase 2 MASH efficacy to pemvidutide.
Cons
- · Lower Phase 2 weight loss than retatrutide (~14.9% vs ~24%).
- · Lacks GIP arm of retatrutide and tirzepatide.
- · No FDA approval, unlike tirzepatide.
- · Smaller trial program than retatrutide.
Retatrutide
Triple receptor (+GIP). Deeper Phase 2 weight loss.
Pros
- · Phase 2 ~24% weight loss vs survodutide ~14.9%.
Cons
- · Still Phase 2.
See Retatrutide →
Pemvidutide
Similar dual GLP-1 + glucagon (Altimmune).
Pros
- · Comparable Phase 2 MASH efficacy.
Cons
- · Phase 2 stage, smaller trial.
See Pemvidutide →
Tirzepatide
FDA-approved dual GLP-1 + GIP. Broader real-world experience.
Pros
- · FDA 2022, deep dataset.
Cons
- · No glucagon arm. Lower energy expenditure.
See Tirzepatide →
COA per supplier
Published, in-house, or shipment-time
Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.
Compare 2 suppliers
| Supplier | Price | COA | Ships | |
|---|---|---|---|---|
| PeptiraUS | $89$8.90/mg · 10mg | COA with shipment | 3 days | Out of stock |
| Ameano PeptidesUS | $95$9.50/mg · 10mg | Sample COA published | 2 days |
Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.
Risk
Limited human data outside trial. These pass with discipline. They do not pass with bravado.
Source · PEPVERA editorialDiscipline
Slow. Phase 3 protocols mirror Retatrutide.
Source · PEPVERA editorialWellness
Hydrate. Eat protein. Sleep eight. Hold a dose for at least two weeks before ascending.
Anti-patterns
- · Do not pair with stimulants late in the day.
- · Do not break the cycle without a planned taper.
- · Do not exceed the dose to chase a deeper sleep response.
Crisis
If the ramp triggers severe anxiety, anhedonia, or persistent gastrointestinal disturbance, stop. Resume after two weeks at half the prior dose. The discipline is the slow climb.
Week 1–2
0.25 mg / wk
Baseline ramp
Week 3–4
0.5 mg / wk
Hold, observe
Week 5–8
1.0–2.0 mg / wk
Ascend
Week 9–12
Research only. See protocol.
Terminus
Draw 10 units.
0.5 mg = 0.10 mL at 5.00 mg/mL. 20.0 doses per vial.
cut · VII · Ameano Peptides
Survodutide · 10mg